The Dimension® Everolimus* assay is for in vitro diagnostic use in the quantitative measurement of everolimus in human whole blood (EDTA) using the Dimension Clinical Chemistry System. The Dimension Everolimus assay is intended for use as an aid in the management of everolimus therapy in kidney, liver, and heart transplant patients.
Transplant medicine depends on reliable results. At Siemens Healthineers, we value the trust of our physicians and laboratories and are committed to providing comprehensive, high-quality testing solutions for transplant patients around the world.
- Provides reliable results with a proprietary automated pretreatment that reduces the risk of matrix effect.
- Delivers sensitive results with a limit of quantitation (1 ng/mL) specified by the Therapeutic Drug Monitoring of Everolimus Consensus Report1, which recommends this to ensure reliable assessment of low concentration dosing.
- Offers good agreement with the LC-MS/MS reference method.
- Helps avoid errors with built-in repeat testing if calculated results exceed 10 ng/mL.
Affinity chrome mediated immunoassay (ACMIA)
No manual pretreatment by user; performed automatically onboard instrument
1.0–25.0 ng/mL (1.0–26.1 nmol/L)
Reagent shelf life
2–8°C until expiration date on product
Reagent onboard stability
Reagent open stability
4 days for liquid reagents/2 days for tablet wells
Turnaround time (TAT)
Limit of quantitation (LOQ)
1.0 ng/mL (1.0 nmol/L)
Limit of detection (LOD)
0.6 ng/mL (0.6 nmol/L)
Limit of blank (LOB)
0.1 ng/mL (0.1 nmol/L)
Manual, not to exceed dilution factor of 2